{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:58:43Z","timestamp":1792403923311,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Brandenburg CAMPUS GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the \u03b2-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Central UMs were defined as lesions up to 5\u00a0mm off the optic disc or fovea radius of 5\u00a0mm. Between January 2011 and July 2020, we treated 56 patients with Ru-106-brachytherapy. The clinical outcomes for recurrence, visual acuity, and radiation-related toxicity were assessed. The follow-up was 66 (6\u2013136) months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 56 patients (56 eyes), 8 (14%) suffered from local recurrence. Six relapsing UM in 19 (32%) patients were located close to the optic disc, and two patients had UM close to the macula (2\/37, 5%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). The overall eye-preservation rate was 89%. The pretreatment visual acuity (VA) was 0.45 and reduced to 0.26 after brachytherapy. Radiation retinopathy or optic neuropathy was detected in 7 (13%) patients and radiation maculopathy in 10 (17.9%). Six patients (11%) underwent enucleation for recurrence or radiation-induced ophthalmopathy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Central UMs are challenging to treat. UMs should be categorized as lesions laterally or medially to the fovea because of different long-term control rates. Localization near the optic disc requires thoughtful management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-024-03381-6","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T03:10:15Z","timestamp":1736565015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ruthenium-106 brachytherapy and central uveal melanoma"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8868-2347","authenticated-orcid":false,"given":"Luise","family":"Grajewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Kneifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"W\u00f6sle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja F.","family":"Ciernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"3381_CR1","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1016\/J.IJROBP.2011.05.012","volume":"81","author":"R Al-Wassia","year":"2011","unstructured":"Al-Wassia R, Dal Pra A, Shun K et al (2011) Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience. Int J Radiat Oncol 81:e455\u2013e462. https:\/\/doi.org\/10.1016\/J.IJROBP.2011.05.012","journal-title":"Int J Radiat Oncol"},{"key":"3381_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/J.BRACHY.2014.04.002","volume":"13","author":"CA Barker","year":"2014","unstructured":"Barker CA, Francis JH, Cohen GN et al (2014) (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence. Brachytherapy 13:584\u2013590. https:\/\/doi.org\/10.1016\/J.BRACHY.2014.04.002","journal-title":"Brachytherapy"},{"key":"3381_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.radonc.2021.01.030","volume":"157","author":"JGM van Beek","year":"2021","unstructured":"van Beek JGM, Ramdas WD, Angi M et al (2021) Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma. Radiother Oncol 157:219\u2013224. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.030","journal-title":"Radiother Oncol"},{"key":"3381_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/J.OPHTHA.2004.11.038","volume":"112","author":"L Bergman","year":"2005","unstructured":"Bergman L, Nilsson B, Lundell G et al (2005) Ruthenium brachytherapy for uveal melanoma, 1979\u20132003: survival and functional outcomes in the Swedish population. Ophthalmology 112:834\u2013840. https:\/\/doi.org\/10.1016\/J.OPHTHA.2004.11.038","journal-title":"Ophthalmology"},{"key":"3381_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/J.PHRO.2018.06.001","volume":"6","author":"IF Ciernik","year":"2018","unstructured":"Ciernik IF, W\u00f6sle M, Krause L, Krayenbuehl J (2018) Optimizing radiosurgery with photons for ocular melanoma. Phys imaging Radiat Oncol 6:83\u201388. https:\/\/doi.org\/10.1016\/J.PHRO.2018.06.001","journal-title":"Phys imaging Radiat Oncol"},{"key":"3381_CR6","doi-asserted-by":"publisher","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ et al (2005) Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (Chicago, Ill 1960) 123:1639\u20131643. https:\/\/doi.org\/10.1001\/ARCHOPHT.123.12.1639","DOI":"10.1001\/ARCHOPHT.123.12.1639"},{"key":"3381_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/BJOPHTHALMOL-2018-313419","volume":"104","author":"M Fil\u00ec","year":"2020","unstructured":"Fil\u00ec M, Trocme E, Bergman L et al (2020) Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of \u22655.5 mm. Br J Ophthalmol 104:26\u201332. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2018-313419","journal-title":"Br J Ophthalmol"},{"key":"3381_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/J.OPHTHA.2011.08.017","volume":"119","author":"PT Finger","year":"2012","unstructured":"Finger PT, Chin KJ, Tena LB (2012) A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve. Ophthalmology 119:415\u2013422. https:\/\/doi.org\/10.1016\/J.OPHTHA.2011.08.017","journal-title":"Ophthalmology"},{"key":"3381_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0002-9394(98)00445-0","volume":"127","author":"K G\u00fcnd\u00fcz","year":"1999","unstructured":"G\u00fcnd\u00fcz K, Shields CL, Shields JA et al (1999) Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 127:579\u2013589. https:\/\/doi.org\/10.1016\/S0002-9394(98)00445-0","journal-title":"Am J Ophthalmol"},{"key":"3381_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5114\/JCB.2021.106191","volume":"13","author":"S Karimi","year":"2021","unstructured":"Karimi S, Arabi A, Siavashpour Z et al (2021) Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: a systematic review and meta-analysis. Undefined 13:358\u2013364. https:\/\/doi.org\/10.5114\/JCB.2021.106191","journal-title":"Undefined"},{"key":"3381_CR11","doi-asserted-by":"publisher","DOI":"10.1055\/A-2268-0985\/ID\/R2961-23\/BIB","author":"F Lalos","year":"2023","unstructured":"Lalos F, Fl\u00fchs D, Guberina M et al (2023) Tumor-und-strahlenbedingte Komplikationen nach Ruthenium-106 Brachytherapie bei kleinen bis mittelgro\u03b2en Aderhautmelanomen (Teil 1). Klin Monbl Augenheilkd. https:\/\/doi.org\/10.1055\/A-2268-0985\/ID\/R2961-23\/BIB","journal-title":"Klin Monbl Augenheilkd"},{"key":"3381_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/ARCHOPHTHALMOL.2011.228","volume":"129","author":"AM Lane","year":"2011","unstructured":"Lane AM, Kim IK, Gragoudas ES (2011) Proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol 129:1127\u20131130. https:\/\/doi.org\/10.1001\/ARCHOPHTHALMOL.2011.228","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"3381_CR13","first-page":"682","volume":"148","author":"P Lommatzsch","year":"1966","unstructured":"Lommatzsch P, Vollmar R (1966) A new way in the conservative therapy of intraocular tumors by means of beta-irradiation (Ruthenium 106) with preservation of vision. PubMed. 148(5):682\u201399","journal-title":"PubMed."},{"key":"3381_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/bjo.75.12.715","volume":"75","author":"PK Lommatzsch","year":"1991","unstructured":"Lommatzsch PK, Lommatzsch R (1991) Treatment of juxtapapillary melanomas. Br J ofOphthalmology 75:715\u2013717. https:\/\/doi.org\/10.1136\/bjo.75.12.715","journal-title":"Br J ofOphthalmology"},{"key":"3381_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12886-022-02521-9\/FIGURES\/3","volume":"22","author":"R Mirshahi","year":"2022","unstructured":"Mirshahi R, Sedaghat A, Jaberi R et al (2022) Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results. BMC Ophthalmol 22:1\u201310. https:\/\/doi.org\/10.1186\/S12886-022-02521-9\/FIGURES\/3","journal-title":"BMC Ophthalmol"},{"key":"3381_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/S41433-022-01944-4","author":"RFJ O\u2019Day","year":"2022","unstructured":"O\u2019Day RFJ, Roelofs KA, Negretti GS et al (2022) Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma. Eye (Lond). https:\/\/doi.org\/10.1038\/S41433-022-01944-4","journal-title":"Eye (Lond)"},{"key":"3381_CR17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/ARCHOPHT.1996.01100140557006","volume":"114","author":"P De Potter","year":"1996","unstructured":"De Potter P, Shields CL, Shields JA et al (1996) Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol 114:1357\u20131365. https:\/\/doi.org\/10.1001\/ARCHOPHT.1996.01100140557006","journal-title":"Arch Ophthalmol"},{"key":"3381_CR18","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/S00417-012-1962-3","volume":"250","author":"A Russo","year":"2012","unstructured":"Russo A, Laguardia M, Damato B (2012) Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 250:1533\u20131540. https:\/\/doi.org\/10.1007\/S00417-012-1962-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3381_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/JAMAOPHTHALMOL.2014.111","volume":"132","author":"MS Sagoo","year":"2014","unstructured":"Sagoo MS, Shields CL, Emrich J et al (2014) Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases. JAMA Ophthalmol 132:697\u2013702. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2014.111","journal-title":"JAMA Ophthalmol"},{"key":"3381_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2415-4-11","volume":"4","author":"A Schmidt-Pokrzywniak","year":"2004","unstructured":"Schmidt-Pokrzywniak A, J\u00f6ckel KH, Bornfeld N, Stang A (2004) Case-control study on uveal melanoma (RIFA): rational and design. BMC Ophthalmol 4:1\u20138. https:\/\/doi.org\/10.1186\/1471-2415-4-11","journal-title":"BMC Ophthalmol"},{"key":"3381_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0161-6420(87)33439-6","volume":"94","author":"JM Seddon","year":"1987","unstructured":"Seddon JM, Gragoudas ES, Egan KM et al (1987) Uveal melanomas near the optic disc or fovea. Visual results after proton beam irradiation. Ophthalmology 94:354\u2013361. https:\/\/doi.org\/10.1016\/S0161-6420(87)33439-6","journal-title":"Ophthalmology"},{"key":"3381_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/ICU.0000000000000041","volume":"25","author":"CL Shields","year":"2014","unstructured":"Shields CL, Manalac J, Das C et al (2014) Choroidal melanoma: Clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol 25:177\u2013185. https:\/\/doi.org\/10.1097\/ICU.0000000000000041","journal-title":"Curr Opin Ophthalmol"},{"key":"3381_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/ARCHOPHT.118.9.1219","volume":"118","author":"CL Shields","year":"2000","unstructured":"Shields CL, Shields JA, Cater J et al (2000) Plaque radiotherapy for uveal melanoma: Long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 118:1219\u20131228. https:\/\/doi.org\/10.1001\/ARCHOPHT.118.9.1219","journal-title":"Arch Ophthalmol"},{"key":"3381_CR24","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1001\/ARCHOPHT.1996.01100140164009","volume":"114","author":"CL Shields","year":"1996","unstructured":"Shields CL, Shields JA, De Potter P et al (1996) Diffuse choroidal melanoma. Clinical features predictive of metastasis. Arch Ophthalmol (Chicago, Ill 1960). 114:956\u2013963. https:\/\/doi.org\/10.1001\/ARCHOPHT.1996.01100140164009","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)."},{"key":"3381_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000518975","volume":"7","author":"MM Sobti","year":"2021","unstructured":"Sobti MM, Edington M, Connolly J et al (2021) Outcomes following notched ruthenium-106 plaque brachytherapy for juxtapapillary choroidal melanomas. Ocul Oncol Pathol 7:411\u2013417. https:\/\/doi.org\/10.1159\/000518975","journal-title":"Ocul Oncol Pathol"},{"key":"3381_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/BJO-2022-322750","author":"S Sreenivasa","year":"2023","unstructured":"Sreenivasa S, W\u00f6sle M, Gager Y et al (2023) Impact of tumour volume and treatment delay on the outcome after linear accelerator-based fractionated stereotactic radiosurgery of uveal melanoma. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/BJO-2022-322750","journal-title":"Br J Ophthalmol"},{"key":"3381_CR27","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/J.PRRO.2014.09.005","volume":"5","author":"V Takiar","year":"2015","unstructured":"Takiar V, Voong KR, Gombos DS et al (2015) A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Pract Radiat Oncol 5:e169\u2013e176. https:\/\/doi.org\/10.1016\/J.PRRO.2014.09.005","journal-title":"Pract Radiat Oncol"},{"key":"3381_CR28","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/S00417-020-04804-7\/METRICS","volume":"258","author":"L Zimmermann","year":"2020","unstructured":"Zimmermann L, Kneifel C, Grajewski L et al (2020) Treatment of radiation-induced maculopathy with fluocinolone acetonide. Graefe\u2019s Arch Clin Exp Ophthalmol 258:2535\u20132539. https:\/\/doi.org\/10.1007\/S00417-020-04804-7\/METRICS","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03381-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03381-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03381-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:05:57Z","timestamp":1766167557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03381-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3381"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03381-6","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images (Figs. 1, 5a and b).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This is an observational retrospective study. Therefore no ethical approval is required in Germany.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"23"}}